Text Size

Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2001 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00003650
First received: November 1, 1999
Last updated: January 20, 2011
Last verified: March 2001
History of Changes
  Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.

PURPOSE: Phase III trial to study the effectiveness of combination chemotherapy in treating children who have non-Hodgkin's lymphoma.


Condition Intervention Phase
Lymphoma
 Drug: asparaginase
Drug: cyclophosphamide
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: dexamethasone
Drug: etoposide
Drug: mercaptopurine
Drug: methotrexate
Drug: methylprednisolone
Drug: mitoxantrone hydrochloride
Drug: prednisone
Drug: vincristine sulfate
Radiation: radiation therapy
 Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Phase III Study of Combination Chemotherapy in Children With T Cell and Pre-B Cell Non-Hodgkin's Lymphoma

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Estimated Enrollment: 200
Study Start Date: June 1998
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   up to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically and/or cytologically confirmed T cell or pre-B cell non-Hodgkin's lymphoma

    • Lymphoblastic or peripheral T cell
    • Stage I, II, III, or IV
  • No anaplastic lymphoma, large cell lymphoma, or small noncleaved cell lymphoma

PATIENT CHARACTERISTICS:

Age:

  • 18 and under

Performance status:

  • Not specified

Life expectancy:

  • Not specified

Hematopoietic:

  • Not specified

Hepatic:

  • Not specified

Renal:

  • Not specified

Other:

  • No prior malignancy
  • No chronic medical or psychological condition
  • No congenital immunodeficiency
  • HIV and HTLV negative
  • Not pregnant

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • No prior chemotherapy

Endocrine therapy:

  • Prior corticosteroids allowed

Radiotherapy:

  • Not specified

Surgery:

  • No prior organ transplant
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00003650

Locations
France
Centre Leon Berard
Lyon, France, 69373
Sponsors and Collaborators
UNICANCER
Investigators
Study Chair: Christophe Bergeron Centre Leon Berard
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

Publications:

ClinicalTrials.gov Identifier: NCT00003650     History of Changes
Other Study ID Numbers: CDR0000066742, FNCLCC-SFOP-96006-LMT-96, EU-98049
Study First Received: November 1, 1999
Last Updated: January 20, 2011
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage I childhood lymphoblastic lymphoma
stage II childhood lymphoblastic lymphoma
stage III childhood lymphoblastic lymphoma
stage IV childhood lymphoblastic lymphoma

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
6-Mercaptopurine
Cytarabine
Methotrexate
Cyclophosphamide
Asparaginase
Daunorubicin
 Dexamethasone
Etoposide
Methylprednisolone Hemisuccinate
Prednisolone
Mitoxantrone
Prednisone
Vincristine
BB 1101
Dexamethasone acetate
Methylprednisolone acetate
Prednisolone acetate
Methylprednisolone
Dexamethasone 21-phosphate
Prednisolone hemisuccinate
Prednisolone phosphate

ClinicalTrials.gov processed this record on May 22, 2013